Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aptinyx Inc (APTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 124,515
  • Shares Outstanding, K 33,562
  • Annual Sales, $ 6,570 K
  • Annual Income, $ -53,280 K
  • 60-Month Beta N/A
  • Price/Sales 18.43
  • Price/Cash Flow N/A
  • Price/Book 0.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.46
  • Number of Estimates 2
  • High Estimate -0.45
  • Low Estimate -0.47
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.44 +7.69%
on 04/18/19
4.70 -21.06%
on 04/03/19
-0.49 (-11.67%)
since 03/18/19
3-Month
3.44 +7.69%
on 04/18/19
6.24 -40.54%
on 01/23/19
-1.53 (-29.20%)
since 01/18/19

Most Recent Stories

More News
Market Trends Toward New Normal in Aclaris Therapeutics, Wingstop, South Jersey Industries, LiveRamp, Garrison Capital, and Aptinyx -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aclaris Therapeutics, Inc....

WING : 77.96 (+2.36%)
SJI : 31.38 (-0.73%)
RAMP : 55.93 (+1.41%)
GARS : 7.20 (-0.55%)
ACRS : 5.52 (+6.36%)
APTX : 3.71 (+2.77%)
Aptinyx to Present at 18th Annual Needham Healthcare Conference

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel,...

APTX : 3.71 (+2.77%)
Data in Parkinson's Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced positive preclinical...

APTX : 3.71 (+2.77%)
Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced an upcoming poster presentation...

APTX : 3.71 (+2.77%)
All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy

Aptinyx Inc. (APTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

APTX : 3.71 (+2.77%)
Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer's & Parkinson's Diseases

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming presentations...

APTX : 3.71 (+2.77%)
Aptinyx Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress

Completed Phase 2 study of NYX-2925 in painful DPN -- did not meet primary endpoint, but NYX-2925 demonstrated robust analgesic activity in a large and mechanistically relevant patient sub-group

APTX : 3.71 (+2.77%)
Aptinyx to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 21, 2019

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will...

APTX : 3.71 (+2.77%)
Aptinyx to Present at Cowen and Company 39th Annual Health Care Conference

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel,...

APTX : 3.71 (+2.77%)
Aptinyx to Present at 8th Annual SVB Leerink Global Healthcare Conference

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel,...

APTX : 3.71 (+2.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade APTX with:

Business Summary

Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in...

See More

Key Turning Points

2nd Resistance Point 3.94
1st Resistance Point 3.83
Last Price 3.71
1st Support Level 3.52
2nd Support Level 3.33

See More

52-Week High 32.25
Fibonacci 61.8% 21.25
Fibonacci 50% 17.85
Fibonacci 38.2% 14.45
Last Price 3.71
52-Week Low 3.44

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar